Latest News and Press Releases

FDA has cleared the new Magstim Rapid TMS system for research and clinical applications, now with FDA clearance in the U.S. for the treatment of pain.

Austin, TX, USA, June 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Alzheimer’s Drug Market Size, Trends and Insights By Type of Drug...

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative...

SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug...

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active...

Today's Marketplace interviews Acumen Pharmaceuticals CEO and Creighton University at the NASDAQ about targeted therapies for Alzheimer's.

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and...

NEW HYDE PARK, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- CareMed, a leading independent Specialty Pharmacy, has been selected by Eisai to be in the pharmacy network for Leqembi® (lecanemab-irmb)....

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical...

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...